Harding, a medicinal chemist, and Wright, a neuroscientist, have been working on their compound since 1992, when they started looking at the impact of the peptide
angiotensin IV on the hippocampus, a brain region involved in spatial learning and short - term memory.
Typically, angiotensins have been linked to blood pressure regulation, but Harding and Wright noticed that
angiotensin IV, or early drug candidates based on it, were capable of reversing learning deficits seen in many models of dementia.